Want to see CI full AI Analyst Report?
EarningsQ2 2026 Earnings Report
CI Q2 2026 EPS Results
Actual EPS$7.78
Consensus EPS$7.60
Beat/MissBeat by +$0.18
One Year Ago EPS$7.20
CI Q2 2026 Revenue Results
Actual Revenue$71.60B
Expected Revenue$70.14B
Beat/MissBeat by +$1.46B
YoY Revenue Growth+6.50%
Earnings Announcement Details
QuarterQ2 2026
Date07/30/2026
TimeBefore Open
Conference CallThursday, July 30, 2026
CI Upcoming Earnings
Cigna's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
CI Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum driven by specialty drug growth, Evernorth and Cigna Healthcare outperformance, AI-enabled clinical initiatives with measurable outcomes, solid revenue and EPS beats, and an upgraded full-year EPS outlook. Offsetting items include PBS earnings pressure from transition investments and economic shifts due to biosimilars, moderating GLP-1 utilization, persistently elevated medical cost trends, IDR-related affordability concerns, and one-time special charges. Overall, the positive drivers (revenue growth, margin gains in Specialty, upgraded guidance, retention/new-business strength, AI initiatives) materially outweigh the manageable challenges described.Company Guidance
Strong Q2 Financial Results
Total revenues of $71.7 billion and adjusted earnings per share of $7.78 in Q2; adjusted after-tax earnings of $2.1 billion for the quarter. Company delivered results ahead of expectations across the enterprise.
Raised Full-Year Guidance
Increased full-year 2026 adjusted earnings per share outlook to at least $30.45, reflecting strong first-half performance while maintaining a prudent view of the environment.
Evernorth Revenue Growth and Specialty Strength
Evernorth revenues grew 6% year-over-year to $61.5 billion; pretax adjusted earnings for Evernorth were $1.7 billion. Specialty & Care Services delivered pretax adjusted earnings of $1.1 billion, up 22% year-over-year, driven by specialty utilization growth, stronger biosimilar and specialty-generic adoption and operating efficiencies.
Cigna Healthcare Growth and Profitability
Cigna Healthcare revenues grew 10% year-over-year to $11.8 billion and pretax adjusted earnings grew 17% year-over-year to $1.3 billion. Medical care ratio (MCR) was 84.5% for the quarter, slightly better than expectations. U.S. employer membership growth and disciplined pricing contributed to results.
Rapid Adoption of Biosimilars / Specialty Generics
Faster-than-expected adoption of biosimilars and specialty generics improved affordability and contributed favorably to earnings; specialty generic penetration exceeded 80% for newer products in the quarter.
AI and Technology Initiatives Producing Measurable Outcomes
New programs (Pharmacy Forward, AI-enabled care coordination) expected to cut time-to-therapy in half and reduce clinician documentation time by up to 50%. Predictive/AI models can expand personalized clinical support to ~20% more customers; customers engaging in programs reduce medical costs by ~ $2,000 per year on average and have seen a 42% reduction in avoidable inpatient stays.
Strong PBM Retention and Selling Season Momentum
Pharmacy Benefit Services closed 2026 with over 97% retention and preliminary 2027 indicators also mid-90s+; total new business secured for 2027 is above the prior two selling seasons combined, indicating strong pipeline momentum for PBS and Signature interest.
Capital Management and Share Repurchases
Repurchased ~900,000 shares for approximately $250 million in Q2. Debt-to-capitalization was 42.8% as of June 30 with expectation to finish the year closer to 40%. Company expects approximately $9 billion of operating free cash flow for the year, mostly back-half weighted.
CI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed